由于癌症和罕见疾病治疗需求强劲，阿斯利康上调了 2024 年销售和利润预测。 AstraZeneca raises 2024 sales and profit forecast on strong cancer and rare disease therapy demand.

英瑞制药公司阿斯利康上调了 2024 年全年销售额和利润预测，理由是其癌症和罕见疾病疗法的需求强劲。 Anglo-Swedish pharmaceutical company AstraZeneca raised its full-year sales and profit forecast for 2024, citing strong demand for its cancer and rare disease therapies. 第二季度收入超过分析师预期，肿瘤学销售额增长 19% 至 53.3 亿美元。 Second-quarter revenues surpassed analyst expectations, with oncology sales growing 19% to $5.33 billion. 首席执行官 Pascal Soriot 将这一增长归功于公司不断发展的药物管道和抗体-药物偶联物等新兴技术，这些技术将在 2030 年以后推动增长。 CEO Pascal Soriot attributed this growth to the company's evolving drug pipeline and emerging technologies, such as antibody-drug conjugates, which are set to drive growth beyond 2030.